Company News

Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) announced that the Japanese Patent Office has granted a patent for the company’s CVac.

Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) announced that the Japanese Patent Office has granted a patent for the company’s CVac.

As quoted in the press release:

The method of use claims secured in patent number 5192020 entitled “Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen” provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.

Click here to read the full Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20

COMMODITIES

Commodities
Gold1806.83-1.58
Silver19.86+0.01
Copper3.60-0.10
Palladium1956.00+11.00
Platinum887.11+1.10
Oil109.39+3.63
Heating Oil3.90+0.07
Natural Gas5.70+0.07

DOWNLOAD FREE REPORTS

×